



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Editorial

Drug repurposing: An effective strategy to accelerate contemporary drug discovery

Because of the high risk, substantial cost and slow pace of new drug discovery and development, drug repurposing (also called repositioning, redirecting, reprofiling) is becoming an attractive and economically viable strategy for identifying new indications for approved or investigational drugs. Great successes have been witnessed in recent years.^{1–5} Particularly, some existing drugs have shown promise for treating SARS-CoV-2 infection and are currently undergoing clinical investigation. For example, remdesivir, a drug candidate for the treatment of Ebola developed by Gilead Sciences, is currently being assessed for treating SARS-CoV-2 infection and has also received approval for emergency use in some regions of the world.⁶ Additionally, various computational methods have been used in drug repositioning, promoting the efficiency and success rates of this approach. Natural products show great promise in drug repositioning because they have been used for various medical purposes for thousands of years; however, these can present their own challenges for drug repurposing. For example, the dosage required for new medical indications frequently differs from that of its original target disease.

In this thematic issue, we present insightful review articles dealing with drug repurposing for novel therapeutics.

Repurposing drugs as anti-infective therapies

One approach to identify and provide novel treatment options rapidly is to repurpose existing drugs as agents against various epidemic viral infectious diseases. Namasivayam *et al.* outline antiviral drug candidates identified using drug repurposing, with their potential mechanism of action and antiviral potency.⁷ Martinez MA discussed whether drug repurposing is the best option for finding effective therapies to eradicate SARS-CoV-2 and other viral human infections.⁸ Kumar *et al.* discuss drug repurposing against SARS-CoV-2 using computational approaches. Among the hits identified by computational methods, 35 candidates were suggested for further development, among which ten drugs are in clinical trials (Phase III and IV) for treating SARS-CoV-2 infection.⁹

Ngan. *et al.* identified preferred drug candidates from their in-house database of approved drugs found *via* anti-SARS-CoV-2 activity screen and the analysis of the inhibitory profiles of the human ether-à-go-go-related gene (hERG), phospholipidosis and many cytotoxicity screens.¹⁰ In addition, the hERG liability of anti-SARS-CoV-2 drugs currently enrolled in clinical trials was also highlighted.

With several US FDA-approved drugs and high barriers to resistance, nucleos(t)ide analogues remain the cornerstone of antiviral therapies. Thus, Roy V. *et al.* summarize recently reported ribonucleoside-based inhibitors of the viral RNA-dependent RNA polymerase (RdRp), which would be suitable for further development as new antiviral nucleosides.¹¹

The polymerases from HIV and HBV, sharing common architecture at their active sites, are the most common drug target for viral inhibition. Emtricitabine and lamivudine are widely used L-nucleoside drugs, targeting HIV reverse transcriptase (RT) and HBV polymerase (Pol). Ruiz *et al.* discuss the structural details of their binding to RT(Pol)/nucleic acid and L-dNTPs. Opportunities for drug development and repurposing of L-nucleos(t)ide drugs were also reviewed.¹²

Cyclophilin A acts as a proviral component in HCV (hepatitis C virus), coronavirus and HIV (human immunodeficiency virus),

* Corresponding author at: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, China. Zhan, P. (zhanpeng1982@163.com, zhanpeng1982@sdu.edu.cn), Yu, B. (zzuyubin@hotmail.com, yubin@zsu.edu.cn), Ouyang, L. (ouyangliang@scu.edu.cn).

thus, its inhibitors were considered to be potential treatments for diverse viral infections. Han *et al.* discuss the feasibility of repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents in the context of the virus lifecycle.¹³

In contrast with the number of newly-launched anti-infectives on the market, the rapid development of cross- or multidrug-resistant strains and the rapidly-increasing prevalence of so-called 'superbugs' are stark. Thus, Jampilek summarized the causes of antimicrobial resistance, discussed drug repurposing strategy in seeking novel anti-infective drugs.¹⁴

Rising incidences and mortalities have drawn attention to *Clostridioides difficile* infections in recent years, which has generated a critical need for new treatments. Here, Chen *et al.* present a refined focus on 16 FDA-approved drugs that will be exploited for the discovery of potential anti-*C. difficile* drugs.¹⁵

Repositioning existing drugs to treat fungal diseases has gained significant attention in recent years; however, such proposed drug-repurposing compounds frequently suffer from unsatisfactory efficacy and pharmacokinetics. Against this background, Donlin *et al.* illustrate the current antifungal drug pipeline and recent strategies to improve existing drugs into novel agents with an original mechanism of action.¹⁶

Recent research reported that auranofin, an approved gold metallic drug, has robust antibacterial potency against multiple Gram-positive bacteria *via* inhibition of thioredoxin reductase, has inspired further development of other gold complexes as antibacterial agents. Thus, Liu *et al.* discuss recent progress in the exploitation of gold complexes as antibacterial agents.¹⁷

Drug repositioning trends in others diseases

Ontology-based analysis of clinical trial data revealed that drug repositioning occurs actively in rare and intractable diseases. In this respect, Sakate *et al.* review the current trends of ontology in rare and intractable diseases, the situation in drug development and an efficient approach to drug repositioning based on drug target gene information.¹⁸

Autophagy has opposing, context-dependent roles in cancer, and interventions to both stimulate and inhibit autophagy have been proposed as cancer therapies. Bu *et al.* describe the application of diverse drug-repurposing methodologies in autophagy for the treatment of cancer and focus on autophagy-targeting drug repurposing to treat malignant neoplasms.¹⁹

Drug repurposing has been attracting mounting attention in the hunt for potential therapeutic agents for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington disease. In this issue, Liu *et al.* focus on summarizing a list of repurposed drugs capable of inhibiting or eliminating toxic protein aggregates and further review their intricate mechanisms of action to optimize the current treatment of neurodegenerative diseases.²⁰

Stroke remains a significant cause of mortality and morbidity worldwide and drug repurposing may represent a shortcut to useful novel therapies. Ghosh *et al.* present an overview of approved drugs that could be repurposed based on their efficacy and safety profiles. Their mechanisms of action were briefly discussed and many repurposed drugs under trials for ischemic stroke therapy were highlighted.²¹

Paradoxically, the repurposing of antidepressants might represent a promising strategy for cancer treatment. Notably, three approved antidepressants have advanced into clinical trials for cancer therapy. Song *et al.* briefly review the anticancer molecular mechanisms of antidepressants and also discuss future directions and the challenges of repurposing antidepressants for anticancer drug discovery.²²

Computational chemistry-based drug repurposing

Recently, deep learning has attracted much attention for its potential in drug repositioning and target prediction. In this special issue Yu *et al.* focus on the basic principles of commonly used deep learning architectures and their applications in drug repositioning and target prediction, and discuss possible approaches in dealing with current challenges, to promote drug repositioning.²³

Arul Murugan *et al.* provide an overview of various deep-learning and machine-learning-based scoring functions for solving classification and ranking problems in drug discovery.²⁴ They focus on studies in which deep-learning and machine-learning models were successfully deployed to find lead compounds for which the experimental verification are available from biology assays.

Structure-based drug repurposing is a popular computational repurposing strategy. Choudhury *et al.* review traditional and modern AI-based in silicon methods and tools used at various steps for structure-based drug discovery pipelines.²⁵ In addition, the role of generative models in generating compounds with scaffolds from repurposable chemical space was highlighted.

Drug discovery by repositioning natural products

Last but by no means least, repurposing natural products has also shown promise for novel therapeutics. Thus, Huang *et al.* analyze the drug repositioning of six prototypical natural products and their derivatives to expose additional drug-disease associations. Besides, challenges and opportunities in future application of natural product-based drug repositioning was also highlighted.²⁶

In recent years, with the continuous development of bio(chem)informatics, drug repurposing has gradually developed into a data-driven innovative drug development strategy. We envision that, with the guidance of bio(chem)informatics, more progress will be made in exploration of the chemical space of existing drugs for additional bioactivities with translational potential.

References

[1] G. Wu, T. Zhao, D. Kang, J. Zhang, Y. Song, V. Namasivayam, J. Kongsted, C. Pannecouque, E. De Clercq, V. Poongavanam, X. Liu, P. Zhan, Overview of

Recent Strategic Advances in Medicinal Chemistry, *J Med Chem.* 62 (21) (2019) 9375–9414.

- [2] V. Parvathaneni, Drug repurposing: a promising tool to accelerate the drug discovery process, *Drug Discov Today*. 24 (10) (2019) 2076–2085.
- [3] S. Pushpakom, M. Pirmohamed, Drug repurposing: progress, challenges and recommendations, *Nat Rev Drug Discov*. 18 (1) (2019) 41–58.
- [4] P. Polamreddy, N. Gattu, The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions, *Drug Discov Today*. 24 (3) (2019) 789–795.
- [5] A. Mullard, The drug-maker's guide to the galaxy, *Nature*. 549 (7673) (2017) 445–447.
- [6] S. Gao, T. Huang, L. Song, S. Xu, Y. Cheng, S. Cherukupalli, D. Kang, T. Zhao, L. Sun, J. Zhang, P. Zhan, X. Liu, Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors, *Acta Pharm Sin B*. 12 (2) (2022) 581–599.
- [7] V. Namasivayam, S. Palaniappan, M. Vanangamudi, Repurposing drugs targeting epidemic viruses, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.04.008>. Apr 12:S1359-6446(22)00155-6.
- [8] M.A. Martinez, Efficacy of repurposed antiviral drugs: Lessons from COVID-19, *Drug Discov Today* (2022), <https://doi.org/10.1016/j.drudis.2022.02.012>. Feb 19:S1359-6446(22)00071-X.
- [9] S. Kumar, S. Kovalenko, S. Bhardwaj, A. Sethi, N.Y. Gorobets, S.M. Desenko, Rathi B. Poonam, Drug repurposing against SARS-CoV-2 using computational approaches Feb 10:S1359-6446(22)00044-7, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.02.004>.
- [10] D.K. Ngan, T. Xu, M. Xia, W. Zheng, R. Huang, Repurposing drugs as COVID-19 therapies: A toxicity evaluation, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.04.001>. Apr 6:S1359-6446(22)00132-5.
- [11] V. Roy, L.A. Agrofoglio, Nucleosides and emerging viruses: A new story, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.02.013>. Feb 19:S1359-6446(22)00070-8.
- [12] F.X. Ruiz, A. Hoang, C.R. Dilmore, J.J. DeStefano, E. Arnold, Structural basis of HIV inhibition by L-nucleosides: Opportunities for drug development and repurposing, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.02.016>. Feb 23:S1359-6446(22)00074-5.
- [13] J. Han, M. Kyu Lee, Y. Jang, W.J. Cho, M. Kim, Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents May 21 00207-0, *Drug Discov Today*. S1359-6446 (22) (2022), <https://doi.org/10.1016/j.drudis.2022.05.016>.
- [14] J. Jampilek, Drug repurposing to overcome microbial resistance, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.05.006>. May 11:S1359-6446(22)00193-3.
- [15] J. Chen, Y. Li, S. Wang, H. Zhang, Y. Du, Q. Wu, H. Wang, Targeting *Clostridioides difficile*: New uses for old drugs, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.03.021>. Apr 4:S1359-6446(22)00131-3.
- [16] M.J. Donlin, M.J. Meyers, Repurposing and optimization of drugs for discovery of novel antifungals, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.04.021>. Apr 27:S1359-6446(22)00170-2.
- [17] Y. Liu, Y. Lu, Z. Xu, X. Ma, X. Chen, W. Liu, Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.02.010>. Feb 19:S1359-6446(22)00069-1.
- [18] R. Sakate, T. Kimura, Drug repositioning trends in rare and intractable diseases, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.01.013>. Jan 29:S1359-6446(22)00035-6.
- [19] F. Bu, J. Zhang, W. Shuai, J. Liu, Q. Sun, L. Ouyang, Repurposing drugs in autophagy for the treatment of cancer: From bench to bedside, *Drug Discov Today*. (2021), <https://doi.org/10.1016/j.drudis.2021.11.013>. Nov 19:S1359-6446(21)00494-3.
- [20] W. Liu, G. Wang, Z. Wang, G. Wang, J. Huang, B. Liu, Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.04.003>. Apr 6:S1359-6446(22)00134-9.
- [21] D. Ghosh, K. Sehgal, B. Sodnar, N. Bhosale, D. Sarmah, A. Datta, A. Chaudhary, K. Kalia, X. Wang, P. Bhattacharya, Drug repurposing for stroke intervention, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.03.003>. Mar 4:S1359-6446(22)00093-9.
- [22] Song Y, Yang X, Yu B. Repurposing antidepressants for anticancer drug discovery. *Drug Discov Today*. 2021 Oct 30:S1359-6446(21)00475-X. doi: 10.1016/j.drudis.2021.10.019.
- [23] J.L. Yu, Q.Q. Dai, G.B. Li, Deep learning in target prediction and drug repositioning: Recent advances and challenges, *Drug Discov Today*. (2021), <https://doi.org/10.1016/j.drudis.2021.10.010>. Oct 27:S1359-6446(21)00448-7.
- [24] N. Arul Murugan, G. Ruba Priya, G. Narahari Sastry, S. Markidis, Artificial intelligence in virtual screening: Models versus experiments, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.05.013>. May 18:S1359-6446(22)00203-3.
- [25] C. Choudhury, N. Arul Murugan, U.D. Priyakumar, Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.03.006>. Mar 14:S1359-6446(22)00112-X.
- [26] B. Huang, Y. Zhang, Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives, *Drug Discov Today*. (2022), <https://doi.org/10.1016/j.drudis.2022.02.007>. Feb 16:S1359-6446(22)00064-2.



Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined the research group of Professor Xinyong Liu as a Lecturer (2010–2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by JSPS (Japan Society for the Promotion of Science) in Japan. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel antiviral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches.



Bin Yu gained his Bachelor degree in Pharmaceutical Sciences (2010) from Zhengzhou University, China, where he also gained his Master degree in Pharmaceutical Engineering (2012). He then achieved his PhD study (2016) for work on chemistry driven drug discovery under the co-supervision of Prof. David Spring (University of Cambridge, UK) and Prof. Hong-Min Liu (Zhengzhou University). Since then, he joined the faculty at School of Pharmaceutical Sciences, Zhengzhou University and was then promoted to a Professorship of Medicinal Chemistry in 2020. His research interests mainly focus on new drug discovery for novel therapeutics. To date, he has published over 130 papers in international peer-reviewed journals. Number of citations (Google Scholar): 3535, H-index = 32, H10-index = 76. He also co-edited two books published by Elsevier and Springer Nature, respectively and filed 25 patents (10 of them licensed). During the last three years, he has been awarded several prestigious awards and granted several funds. He currently serves as the Faculty Member of Faculty Opinions (formerly known as F1000 Prime), associate editor of *Frontiers in Drug Discovery*, section editor of *Current Medicinal Chemistry*, review editor of *Frontiers in Chemistry*, editorial board member of *Nature Reviews Drug Discovery* (Chinese version), *Acta Pharmaceutica Sinica B*, *Chinese Chemical Letters*, and *Chinese Journal of Natural Medicines* as well as the managing guest editor of *Drug Discovery Today*, *European Journal of Medicinal Chemistry*, *Pharmacological Research*, *Current Medicinal Chemistry*, *Frontiers in Pharmacology*, *Current Topics in Medicinal Chemistry* and *Chemical Biology & Drug Design*.



Liang Ouyang received his PhD in medicinal chemistry from West China School of Pharmacy, Sichuan University, in 2010. He is now a professor at the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He has a longstanding interest in the design and synthesis of drugs based on original autophagy targets, the application of lead compound screening, the development of new drug target recognition methods and drug discovery, taking advantage of interdisciplinary approaches, including systems biology, structural biology, computer-aided drug design, medicinal chemistry, chemical biology, and molecular biology.

Peng Zhan*

*Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, China
China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, 250012 Jinan, Shandong, China*

Bin Yu

School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

Liang Ouyang

State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China